Dataset from Randomized, Double-blind, Placebo-controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Combination With Bendamustine and Rituximab (BR) in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
收藏NIAID Data Ecosystem2026-05-02 收录
下载链接：
https://doi.org/10.25934/PR00007753
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to examine the safety and efficacy of Ibrutinib administered in
combination with bendamustine and rituximab in patients with relapsed or refractory chronic
lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
创建时间：
2025-01-10
